The application of anti-cyclic citrullinated peptide autoantibody and soluble HLA-DR tests to the detection of early rheumatoid arthritis in New Zealand patients.

Not Applicable

Completed

• Conditions: Rheumatoid arthritis; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12606000277549
• Lead Sponsor: isa Stamp

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-07-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Patients who have been assessed by a rheumatologist and deemed to have undifferentiated inflammatory arthritis defined as history, examination and laboratory findings suggesting an inflammatory disorder, but which are not diagnostic of or classifiable as a specific rheumatic inflammatory condition 2. willing and able to provide informed consent

Exclusion Criteria

1. Presence of chronic infection or other severe concomitant medical illness or psychiatric disease.2. Pregnant or breast-feeding females and female subjects of child bearing age who are not practising medically approved methods of contraception.3. HIV positive patients4. History of drug abuse that would interfere with the ability to comply with the study protocol5. Patients with active, concomitant malignancies.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnosis of RA[At 2 years]

Secondary Outcome Measures

Name	Time	Method
il[Nil]